NF1 gene and neurofibromatosis 1

被引:6
作者
Rasmussen, SA
Friedman, JM
机构
[1] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30341 USA
[2] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
关键词
neurofibromatosis; 1;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant condition caused by mutations of the NF1 gene, which is located at chromosome 17q11.2, NF1 is believed to be completely penetrant, but substantial variability in expression of features occurs. Diagnosis of NF1 is based on established clinical criteria. The presentation of many of the clinical features is age dependent. The average life expectancy of patients with NF1 is probably reduced by 10-15 years, and malignancy is the most common cause of death. The prevalence of clinically diagnosed NF1 ranges from 1/2,000 to 1/5,000 in most population-based studies, A wide variety of NF1 mutations has been found in patients with NF1, but no frequently recurring mutation has been identified. Most studies have not found an obvious relation between particular NF1 mutations and the resulting clinical manifestations. The variability of the NF1 phenotype, even in individuals with the same NF1 gene mutation, suggests that other factors are involved in determining the clinical manifestations, but the nature of these factors has not yet been determined. Laboratory testing for NF1 mutations is difficult. A protein truncation test is commercially available, but its sensitivity, specificity, and predictive value have not been established, No general, population-based molecular studies of NF1 mutations have been performed. At this time, it appears that the benefits of population-based screening for clinical features of NF1 would not outweigh the costs of screening.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 66 条
[21]   BENIGN NEUROFIBROMAS IN TYPE-1 NEUROFIBROMATOSIS (NF1) SHOW SOMATIC DELETIONS OF THE NF1 GENE [J].
COLMAN, SD ;
WILLIAMS, CA ;
WALLACE, MR .
NATURE GENETICS, 1995, 11 (01) :90-92
[22]   METHODS FOR RAPID DETECTION OF A RECURRENT NONSENSE MUTATION AND DOCUMENTATION OF PHENOTYPIC FEATURES IN NEUROFIBROMATOSIS TYPE-1 PATIENTS [J].
DUBLIN, S ;
RICCARDI, VM ;
STEPHENS, K .
HUMAN MUTATION, 1995, 5 (01) :81-85
[23]  
EASTON DF, 1993, AM J HUM GENET, V53, P305
[24]  
Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO
[25]  
2-U
[26]  
FULLER L C, 1989, Neurofibromatosis, V2, P278
[27]   NEUROFIBROMATOSIS TYPE-1 IN ISRAEL - SURVEY OF YOUNG-ADULTS [J].
GARTY, BZ ;
LAOR, A ;
DANON, YL .
JOURNAL OF MEDICAL GENETICS, 1994, 31 (11) :853-857
[28]   The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 [J].
Gutmann, DH ;
Aylsworth, A ;
Carey, JC ;
Korf, B ;
Marks, J ;
Pyeritz, RE ;
Rubenstein, A ;
Viskochil, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :51-57
[29]   Segmental neurofibromatosis: Case reports and review [J].
Hager, CM ;
Cohen, PR ;
Tschen, JA .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (05) :864-869
[30]   DISTRIBUTION OF 13 TRUNCATING MUTATIONS IN THE NEUROFIBROMATOSIS-1 GENE [J].
HEIM, RA ;
KAMMORGAN, LNW ;
BINNIE, CG ;
CORNS, DD ;
CAYOUETTE, MC ;
FARBER, RA ;
AYLSWORTH, AS ;
SILVERMAN, LM ;
LUCE, MC .
HUMAN MOLECULAR GENETICS, 1995, 4 (06) :975-981